# Joint Initiative in Vaccine Economics, Phase 6

> **NIH ALLCDC U01** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2020 · $300,000

## Abstract

PROJECT SUMMARY
The proposed studies will provide critical information to inform immunization policies and practices in the
United States. Immunizations are among the most effective health interventions available in the US, with more
than 40,000 early deaths and 20 million cases of disease averted within each vaccinated birth cohort.
Immunizations are also among the most efficient from an economic perspective. Many older vaccines are cost-
saving, while newer vaccines require an investment for health benefits but typically yield cost-effectiveness
ratios within a range considered to be cost-effective. As newer vaccines are associated with higher prices and
also more likely to avert morbidity than mortality, economic evaluation can provide insights into the value of a
new vaccine by weighing trade-offs among the additional investments required, averted disease costs,
projected health benefits, and adverse events. The goal of these studies, as part of the Joint Initiative in
Vaccine Economics (JIVE), is to address two highly-relevant topics in immunization policy and practice: the
economic attractiveness of a hypothetical vaccine for respiratory syncytial virus (RSV) and the costs and
potential health benefits of interoperability between provider practices and statewide immunization information
systems.
Using economic evaluation and decision analysis methods, we will (1) measure the economic burden
associated with RSV for patients, caregivers, and family members at both the patient and population level; (2)
evaluate projected health and economic outcomes for a hypothetical RSV vaccine, including costs, quality-
adjusted life years, and incremental cost-effectiveness ratios, and (3) evaluate practice-level costs and benefits
of interoperability between provider practice electronic health records and a statewide immunization
information system. Methods will include primary data collection, health utility elicitation, discrete choice
experiments, economic evaluation, simulation modeling, dynamic transmission modeling, as well as qualitative
analysis.

## Key facts

- **NIH application ID:** 9953916
- **Project number:** 5U01IP001104-03
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Lisa A. Prosser
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** ALLCDC
- **Fiscal year:** 2020
- **Award amount:** $300,000
- **Award type:** 5
- **Project period:** 2018-09-01 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9953916

## Citation

> US National Institutes of Health, RePORTER application 9953916, Joint Initiative in Vaccine Economics, Phase 6 (5U01IP001104-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9953916. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*